Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Genomic Disruption of the Histone Methyltransferase SETD2 in Chronic Lymphocytic Leukemia

Blood (2015) 126 (23): 365.

https://doi.org/10.1182/blood.V126.23.365.365

Published: 2015

Journal Articles

Deep-Sequencing Reveals the Molecular Landscape of Splenic Marginal Zone Lymphoma: Biological and Clinical Implications

Blood (2014) 124 (21): 76.

https://doi.org/10.1182/blood.V124.21.76.76

Published: 2014

Journal Articles

Tracking Subclonal Mutations in IGHV-Mutated CLL with Progressive Disease

Matthew JJ Rose-Zerilli, PhD, Gibson Jane, PhD, Jun Wang, PhD, William J Tapper, PhD, Helen Parker, PhD, Anton Parker, Zadie Davis, Anne Catherine Gardiner, Jade Forster, Andrew J Steele, PhD, Renata Walewska, Helen McCarthy, Andrew Collins, PhD, David G Oscier, MD, Jonathan C Strefford, PhD

Blood (2014) 124 (21): 1962.

https://doi.org/10.1182/blood.V124.21.1962.1962

Published: 2014

Journal Articles

ZAP70 Methylation Is An Independent Prognostic Biomarker For Front Line Therapy Of Chronic Lymphocytic Leukemia : Results From The UK LRF CLL4 Trial

Anton Parker, Ben Gregory, Zadie Davis, Monica Else, MA, MSc, Matthew JJ Rose-Zerilli, PhD, Jonathan C Strefford, Daniel Catovsky, MD, DSc(Med), David Oscier

Blood (2013) 122 (21): 4137.

https://doi.org/10.1182/blood.V122.21.4137.4137

Published: 2013

Journal Articles

Mutations In XPO1, POT1, BIRC3 and FBXW7 collectively Predict Poor Outcome At Diagnosis In CLL and MBL Independent From The SF3B1 and NOTCH1 Status

Nils Winkelmann, MD, Mathew J Rose-Zerilli, PhD, Jade Forster, Mathew Parry, PhD, Anton Parker, BSc, Anne Gardiner, Zadie Davies, BSC, Andrew J Steele, PhD, Helen Parker, PhD, Andrew Collins, PhD, Nick C.P. Cross, PhD, David Oscier, MD, Jonathan C Strefford

Blood (2013) 122 (21): 4138.

https://doi.org/10.1182/blood.V122.21.4138.4138

Published: 2013

Journal Articles

The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial

David G. Oscier, Matthew J. J. Rose-Zerilli, Nils Winkelmann, David Gonzalez de Castro, Belen Gomez, Jade Forster, Helen Parker, Anton Parker, Anne Gardiner, Andrew Collins, Monica Else, Nicholas C. P. Cross, Daniel Catovsky, Jonathan C. Strefford

Blood (2013) 121 (3): 468–475.

https://doi.org/10.1182/blood-2012-05-429282

Published: 2013

Includes: Supplemental data

Journal Articles

The Correlation Between Deletion Architecture, ATM Mutational Status and BIRC3 Disruption in 11q-Deleted CLL

Matthew JJ Rose-Zerilli, PhD, Jade Forster, Helen Parker, PhD, Anton Parker, Ana E Rodríguez, Tracy Chaplin, Anne Gardiner, Andrew Collins, PhD, Bryan D Young, PhD, Tatjana Stankovic, MD., PhD, David Oscier, MD, Jonathan C. Strefford, BSc, PhD

Blood (2012) 120 (21): 658.

https://doi.org/10.1182/blood.V120.21.658.658

Published: 2012

Journal Articles

Biallelic ATM Inactivation Significantly Reduces Survival in Chronic Lymphocytic Leukemia Patients Treated with Alkylating Agent/Purine Analogue Therapy: Results From the UKCLL4 Trial

Anna Skowronska, Gulshanara Ahmed, Ceri E Oldreive, PhD, David Oscier, MD, Anton Parker, Martin J.S. Dyer, MA, DPhil, Estella Matutes, MD, PhD, A. Malcolm R Taylor, PhD, Paul AH Moss, MD PhD, Tatjana Stankovic, MD PhD

Blood (2011) 118 (21): 467.

https://doi.org/10.1182/blood.V118.21.467.467

Published: 2011

Journal Articles

Telomere Length Is An Independent Predictor of Outcome After Therapy in CLL: Results From the UKCLL4 Trial,

Anton Parker, Jade Forster, Stacey Reichter, David Gonzalez de Castro, PhD, Daniel Catovsky, MD, David Oscier, MD

Blood (2011) 118 (21): 3884.

https://doi.org/10.1182/blood.V118.21.3884.3884

Published: 2011

Journal Articles

The Outcome of CLL Patients with 97% Identity to Germline Is Inferior to Other ‘Mutated’ Cases Defined by a 98% Cut off

Zadie Davis, PhD, Anton Parker, Daniel Catovsky, MD, David Oscier, MD

Blood (2011) 118 (21): 2842.

https://doi.org/10.1182/blood.V118.21.2842.2842

Published: 2011

Journal Articles

Sequential SNP6.0 Microarray Analysis In Rai Stage 0 CLL Patients with Either Stable or Progressive Identifies Genomic Evolution In Both Cohorts

Matthew JJ Rose-Zerilli, PhD, Miqdad Rajibali, BSc, Helen Parker, PhD, Anton Parker, BSc, Anne Catherine Gardiner, BSc, Zadie Davis, PhD, Sarah Mold, BSc, Sharron Glide, BSc, Tracy Chaplin, Bryan D Young, BSc, PhD, David Graham Oscier, Jonathan C. Strefford, BSc, PhD

Blood (2010) 116 (21): 1696.

https://doi.org/10.1182/blood.V116.21.1696.1696

Published: 2010

Journal Articles

Deletion Size Influences Clinical Outcome In Patients with Chronic Lymphocytic Leukemia; 13q Deletion Anatomy, Cooperating Lesions and Cancer Pathogenesis

Helen Parker, PhD, Matthew JJ Rose-Zerilli, PhD, Anton Parker, BSc, Tracy Chaplin, Anne Catherine Gardiner, BSc, Mike Griffiths, Andrew Collins, PhD, Bryan D Young, BSc, PhD, David Graham Oscier, Jonathan C. Strefford, BSc, PhD

Blood (2010) 116 (21): 757.

https://doi.org/10.1182/blood.V116.21.757.757

Published: 2010

Journal Articles

13q Deletion Size Predicts Disease Progression and Response to Treatment in Patients with Chronic Lymphocytic Leukaemia.

Jonathan C Strefford, PhD, Helen Parker, PhD, Anton Parker, BSc, Hazel Robinson, PhD, Tracy Chaplin, MSc, Xiao-He Chen, PhD, David Bunyan, PhD, Anne Gardiner, BSc, Bryan D Young, PhD, David Graham Oscier, MD

Blood (2009) 114 (22): 671.

https://doi.org/10.1182/blood.V114.22.671.671

Published: 2009

Journal Articles

Epigenetic Regulation of ZAP70 in Chronic Lymphocytic Leukemia.

Anton Parker, Shilu Amin, Tricia Zwiefelhofer, Ben Gregory, Helen White, PhD, Oliver Giles Best, PhD, Nick Cross, PhD, Jelena Mann, PhD, Mathias Ehrich, MD, David Graham Oscier, MD

Blood (2008) 112 (11): 2246.

https://doi.org/10.1182/blood.V112.11.2246.2246

Published: 2008

Journal Articles

HOX Genes - Candidate Tumor Suppressor Genes in Adult and Childhood Leukemia.

Gordon R. Strathdee, Tessa L. Holyoake, Alyson Sim, Anton Parker, David G. Oscier, Junia V. Melo, Stefan Meyer, Tim Eden, Anne M. Dickinson, Joanne Mountford, Heather G. Jorgensen, Richard Soutar, Robert Brown

Blood (2007) 110 (11): 2641.

https://doi.org/10.1182/blood.V110.11.2641.2641

Published: 2007

Journal Articles

Splenic Marginal Zone Lymphoma Shows a Distinct Pattern of DNA Copy Number Aberrations That Correlates with Tumor Characteristics and Predicts Disease Outcome.

Jose A. Martinez-Climent, MD, PhD, Cristina Robledo, MSc, Manuela Mollejo, MD, Anton Parker, MD, Juan L. Garcia, PhD, Carlos Panizo, MD, Lorena Fontan, PhD, Vicente Fresquet, PhD, Ellen D. Remstein, MD, Sara Mould, MD, Ahmet Dogan, MD, Mark Law, MD, Isabel Marugan, MD, Maria J. Terol, MD, Esperanza Vizcarra, MD, David Graham Oscier, MD, Miguel A. Piris, MD, Jose M. Hernandez-Rivas, MD

Blood (2006) 108 (11): 2422.

https://doi.org/10.1182/blood.V108.11.2422.2422

Published: 2006

Journal Articles

Zap70 Methylation Correlates with Zap70 Expression in Chronic Lymphocytic Leukemia.

David Graham Oscier, MD, Anton Parker, BSc, Zadie Davis, MSc, Wirtz Michaela, MSc, Schmitz Oliver, PhD, Jenny Orchard, MD, Martin Corcoran, PhD

Blood (2004) 104 (11): 962.

https://doi.org/10.1182/blood.V104.11.962.962

Published: 2004

NARROW

Genomic Disruption of the Histone Methyltransferase SETD2 in Chronic Lymphocytic Leukemia

Deep-Sequencing Reveals the Molecular Landscape of Splenic Marginal Zone Lymphoma: Biological and Clinical Implications

Tracking Subclonal Mutations in IGHV-Mutated CLL with Progressive Disease

ZAP70 Methylation Is An Independent Prognostic Biomarker For Front Line Therapy Of Chronic Lymphocytic Leukemia : Results From The UK LRF CLL4 Trial

Mutations In XPO1, POT1, BIRC3 and FBXW7 collectively Predict Poor Outcome At Diagnosis In CLL and MBL Independent From The SF3B1 and NOTCH1 Status

The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial

The Correlation Between Deletion Architecture, ATM Mutational Status and BIRC3 Disruption in 11q-Deleted CLL

Biallelic ATM Inactivation Significantly Reduces Survival in Chronic Lymphocytic Leukemia Patients Treated with Alkylating Agent/Purine Analogue Therapy: Results From the UKCLL4 Trial

Telomere Length Is An Independent Predictor of Outcome After Therapy in CLL: Results From the UKCLL4 Trial,

The Outcome of CLL Patients with 97% Identity to Germline Is Inferior to Other ‘Mutated’ Cases Defined by a 98% Cut off

Sequential SNP6.0 Microarray Analysis In Rai Stage 0 CLL Patients with Either Stable or Progressive Identifies Genomic Evolution In Both Cohorts

Deletion Size Influences Clinical Outcome In Patients with Chronic Lymphocytic Leukemia; 13q Deletion Anatomy, Cooperating Lesions and Cancer Pathogenesis

13q Deletion Size Predicts Disease Progression and Response to Treatment in Patients with Chronic Lymphocytic Leukaemia.

Epigenetic Regulation of ZAP70 in Chronic Lymphocytic Leukemia.

HOX Genes - Candidate Tumor Suppressor Genes in Adult and Childhood Leukemia.

Splenic Marginal Zone Lymphoma Shows a Distinct Pattern of DNA Copy Number Aberrations That Correlates with Tumor Characteristics and Predicts Disease Outcome.

Zap70 Methylation Correlates with Zap70 Expression in Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only